Compare KMX & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMX | LEGN |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.9B |
| IPO Year | 1997 | 2020 |
| Metric | KMX | LEGN |
|---|---|---|
| Price | $39.26 | $22.53 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 18 | 13 |
| Target Price | $42.08 | ★ $69.58 |
| AVG Volume (30 Days) | ★ 4.2M | 2.3M |
| Earning Date | 12-18-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.67 | N/A |
| EPS | ★ 3.04 | N/A |
| Revenue | ★ $27,834,194,000.00 | $909,045,000.00 |
| Revenue This Year | N/A | $68.52 |
| Revenue Next Year | $0.99 | $48.63 |
| P/E Ratio | $12.91 | ★ N/A |
| Revenue Growth | 0.14 | ★ 74.75 |
| 52 Week Low | $30.26 | $21.19 |
| 52 Week High | $89.47 | $45.30 |
| Indicator | KMX | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 50.57 | 33.52 |
| Support Level | $37.76 | $21.19 |
| Resistance Level | $39.59 | $23.24 |
| Average True Range (ATR) | 1.44 | 1.04 |
| MACD | -0.08 | 0.18 |
| Stochastic Oscillator | 39.66 | 21.26 |
CarMax sells, finances, and services used and new cars through a chain of over 250 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales were 83% of fiscal 2025 revenue and wholesale about 17%, with the remaining portion composed of extended service plans and repair. In fiscal 2025, the company retailed and wholesaled 789,050 and 544,312 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the US but still estimates that it had only about 3.7% US market share of vehicles 0-10 years old in calendar 2024. It seeks over 5% share. CarMax is based in Richmond, Virginia.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.